The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter II: emerging transformational cytotherapies.
Hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for inherited anemias, immunodeficiencies or hematologic malignancies. A major complication of allo-HSCT associated with high transplant-related mortality rates is graft-versus-host disease (GvHD). Current and future clinical benefits in HSCT enabled by advances in hematopoietic stem cells, mesenchymal stem cells, Tregs and natural killer cells technologies are reviewed here and discussed. Among these evolutions, based on the need for mesenchymal stem cells to be recruited by an inflammatory environment, the development and use of novel GvHD biomarkers could be explored further to deliver the right pharmaceutical to the right patient at the right time. The successful commercialization of cytotherapeutics to efficiently manage GvHD will create a virtuous 'halo' effect for regenerative medicine.
Sloan Fellow, London Business School, London, UK.
Alain A
AA
Vertès
D000740:Anemia / Q000276:immunology / Q000628:therapy; D000818:Animals; D015415:Biomarkers; D064987:Cell- and Tissue-Based Therapy / Q000379:methods / Q000639:trends; D006086:Graft vs Host Disease / Q000276:immunology / Q000401:mortality / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy; D006410:Hematopoiesis / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000276:immunology / Q000628:therapy; D020127:Recovery of Function / Q000276:immunology*; D044968:Regenerative Medicine / Q000379:methods / Q000639:trends
D015415:Biomarkers
GvHD; NK cells; Tregs; graft-versus-host disease; hematopoietic stem cells; mesenchymal stem cells; transplantation